Myriad Genetics Soars 9.64% to 2025 High on Leadership Shift, Institutional Buys and Earnings Beat

Shares of Myriad Genetics (MYGN) surged 2.41% on Thursday, marking a three-day rally that lifted the stock 9.64% overall. The price reached its highest level since August 2025, with an intraday gain of 5.47%, signaling renewed investor confidence in the diagnostics firm. This momentum follows a strategic shift in leadership and a series of institutional investments that underscore the company’s focus on oncology and women’s health diagnostics.

Recent developments include the appointment of Ben R. Wheeler as Chief Financial Officer on August 18, 2025, a move aimed at stabilizing financial operations amid challenges like negative net income and a return on equity of -70.03%. Wheeler’s healthcare and finance expertise is seen as a critical step toward aligning the company with long-term growth objectives, particularly in expanding its portfolio of hereditary cancer tests and pharmacogenomics solutions.

Institutional investors have also shown renewed interest, with Nuveen LLC acquiring 1.28% of shares in Q2 2025 and Vanguard Group Inc. and the Public Sector Pension Investment Board increasing holdings in August. While Invesco Ltd. and Wellington Management Group adjusted their positions, the overall institutional ownership of 99.02% highlights strong backing for Myriad’s strategic direction. This support contrasts with mixed analyst ratings, which include three “buy” calls, eight “hold” recommendations, and three “sell” assessments, reflecting cautious optimism about the company’s growth potential.

Myriad’s recent Q2 2025 earnings report, which exceeded revenue expectations and revised full-year guidance upward, further bolstered market sentiment. Despite missing EPS targets, the company emphasized momentum in its oncology and women’s health segments, particularly through products like the MyRisk Hereditary Cancer Test and BRACAnalysis CDx. Collaborations with ANGLE plc and research institutions are also advancing liquid biopsy technologies, positioning Myriad to compete in a rapidly evolving precision medicine landscape.

Looking ahead, the firm’s participation in major healthcare conferences in September 2025, including the Wells Fargo and Morgan Stanley events, is expected to amplify visibility and investor engagement. These platforms will highlight Myriad’s focus on innovation in cancer diagnostics and its efforts to address unmet needs in preventive healthcare. While risks such as regulatory challenges and market volatility persist, the company’s strong R&D pipeline and recent financial restructuring efforts suggest a strategic path toward sustainable growth.